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Mortality of treated HIV-1 positive individuals
according to viral subtype in Europe and Canada:
collaborative cohort analysis
The Antiretroviral Therapy Cohort Collaboration (ART-CC), Canadian
Observational Cohort Collaboration (CANOC), The UK Collaborative
HIV Cohort Study (UK CHIC), the Collaboration of Observational
HIV Epidemiological Research in Europe (COHERE)
Objectives: To estimate prognosis by viral subtype in HIV-1-infected individuals from
start of antiretroviral therapy (ART) and after viral failure.
Design: Collaborative analysis of data from eight European and three Canadian
cohorts.
Methods: Adults (N>20 000) who started triple ART between 1996 and 2012 and
had data on viral subtype were followed for mortality. We estimated crude and
adjusted (for age, sex, regimen, CD4þ cell count, and AIDS at baseline, period of
starting ART, stratified by cohort, region of origin and risk group) mortality hazard
ratios (MHR) by subtype. We estimated MHR subsequent to viral failure defined as
two HIV-RNA measurements greater than 500 copies/ml after achieving viral
suppression.
Results: The most prevalent subtypes were B (15 419; 74%), C (2091; 10%), CRF02AG
(1057; 5%), A (873; 4%), CRF01AE (506; 2.4%), G (359; 1.7%), and D (232; 1.1%).
Subtypes were strongly patterned by region of origin and risk group. During 104649
person-years of observation, 1172/20 784 patients died. Compared with subtype B,
mortality was higher for subtype A, but similar for all other subtypes.MHR for A versus B
were 1.13 (95% confidence interval 0.85,1.50) when stratified by cohort, increased to
1.78 (1.27,2.51) on stratification by region and risk, and attenuated to 1.59 (1.14,2.23)
on adjustment for covariates. MHR for A versus B was 2.65 (1.64,4.28) and 0.95
(0.57,1.57) for patients who started ARTwith CD4þ cell count below, or more than, 100
cells/ml, respectively. There was no difference in mortality between subtypes A, B and C
after viral failure.
Conclusion: Patients with subtype A had worse prognosis, an observation which may
be confounded by socio-demographic factors.
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Introduction
HIV-1 is a highly diverse virus that is classified into four
groups: M (major), O (outlier), N (nonmajor nonoutlier)
[1], and group P, a recently discovered ‘‘proposed’’ new
group [2]. The vast majority of HIV-1 infections are
groupM, which includes at least nine subtypes (clades) [3]
and an increasing number of circulating recombinant
forms (CRFs) [4]. The early spread of HIV-1 within
Canada, the United States, and Western Europe was due
to group M, subtype B infection, which occurred mainly
among MSM and injection drug user (IDU) commu-
nities. Diagnostic and monitoring tests, as well as our
understanding of the natural history, molecular biology
and responses to antiretroviral therapy (ART), were
established primarily for subtype B because this was
dominant in Europe and North America. Worldwide
however, subtype C, which is most often seen in
heterosexuals, accounts for about half of currently
infected individuals and the majority of new HIV-1
infections [5]. An increasing proportion of infections in
Europe and Canada are non-B due to migration,
particularly from Africa, with further secondary local
transmission [6,7].
Monitoring viral diversity is important because differ-
ences between subtypes have been reported in transmis-
sibility, disease pathogenesis [8], pretreatment progression
[9], accuracy of viral load monitoring by conventional
assays [10], genetic barriers to ART resistance [11,12],
response to treatment [13–16], and rate of progression to
AIDS [17–19]. The impact of these differences on
prognosis in the ART era may be substantial and
dependent on choice of ARTregimen [20,21]. Published
studies have been limited by small numbers of patients
with individual subtypes, and short follow-up [13,22].
Several studies have compared subtype B with non-B
subtypes grouped together [23,24], but there may be
differences in prognosis between non-B subtypes. Large
collaborations of cohorts are required to compare
prognosis for clinical events between patients infected
with different viral subtype [25].
The relationship of HIV subtype with prognosis may be
confounded by social and demographic as well as clinical
characteristics. In particular, subtypes cluster by geo-
graphic origin and transmission risk group. Therefore
we compared mortality by subtype in patients starting
ART accounting for their region of origin and risk
group. Variation in outcomes would warrant further
study of differences in response to specific ART
regimens and development of viral resistance [21].
Our objectives were to characterize the frequencies of
HIV subtypes in this population, compare demographic
and clinical characteristics and estimate prognosis for
mortality after starting ART and after viral failure by
subtype or CRF.
Methods
We combined data from three Canadian and eight
European cohorts: Montreal (Canada) [26], the UK
Collaborative HIV Cohort (UK CHIC) [27], and those
included in the ART Cohort Collaboration (ART-CC)
which had more than 100 patients with data on viral
subtype. Cohorts from USA were excluded as they do
not exhibit large diversity in HIV subtypes. Details of
ART-CC appear elsewhere (http://www.art-cohort-
collaboration.org) [28]: Cohorts have been approved
by their ethics committees or institutional review boards,
use standardized methods of data collection, and schedule
follow-up visits at least every 6 months.
Included patients had confirmed HIV infection, were
aged at least 16 years and started combination ART [at
least two nucleoside reverse transcriptase inhibitors
(NRTI) plus boosted protease inhibitor or nonnucleoside
reverse transcriptase inhibitor (NNRTI)] between 1996
and 2012 and were without prior exposure to
antiretroviral drugs. Eligible patients had data on viral
subtype, region of origin, CD4þ and AIDS diagnosis at
ART start. Patients were followed for mortality from
ART start to cohort-specific database close date, which
varied between cohorts from 31 December 2009 to
31 March 2012. Patients were considered lost to follow-
up if there was a lag of more than 1 year between the dates
the patient was last known to be alive and administrative
censoring.
European cohorts recorded country of origin and/or
ethnicity. Cohorts from mainland Europe had data on
country of origin for migrants, but did not always record
country of origin for those born in the home country. We
assumed that patients treated in the United Kingdomwho
were identified as black Caribbean were from Europe as
they were likely to have been born in the United
Kingdom, whereas those who identified as black African
were likely to be recent immigrants and were assumed to
be from sub-Saharan Africa (SSA). We used a combi-
nation of ethnicity and country of origin to allocate
patients to regions defined by the United Nations
International Standard (unstats.un.org/unsd/methods/
m49/m49.htm). Patients from west, east and southern
Africa were grouped as SSA because some cohorts used
the term ‘‘black African’’. We used the following final
classification of region of origin: Europe/SSA/N. Africa/
Middle East/Asia/Australasia/N. America/Central and S.
America/Canada First Nations.
We compared demographic and clinical characteristics at
ART start by subtype. The Kaplan–Meier method was
used to estimate cumulative mortality by subtype. We
estimated crude mortality rates per 1000 person-years
overall and by subtype. Because subtype was highly
correlated with region of origin and transmission risk we
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fitted a series of stratified Cox models to estimate crude
and adjusted between-subtype mortality hazard ratios
(MHR) from ART start, with subtype B as the
comparator. We estimated MHR that were crude;
stratified by cohort; additionally stratified by region of
origin and risk group; additionally adjusting for age, sex,
CD4þ and AIDS at baseline, period of starting ART
(1996–2002, 2003–2009), and regimen (protease inhibi-
tor-based, NNRTI-based, other). We did not adjust for
viral load at ART start as it was not predictive in
multivariable models and inclusion would have reduced
sample size. We used Akaike Information Criteria (AIC)
to compare model fit. Because IDUs have worse
prognosis than other risk groups, comparisons excluding
IDU were made. As subtype was strongly related to
region of origin, we repeated analyses restricting to
heterosexuals and MSM of European (EU) origin. We
also estimated MHR comparing the most prevalent
subtypes (A, B, and C) across the EU and SSA patient
populations within the same model. In sensitivity
analyses, we estimated adjusted MHR: restricting to
white heterosexuals; excluding the UKCHIC cohort as it
included black Caribbean patients; only including UK
CHIC. To examine whether differences in mortality were
mostly due to deaths soon after starting ART, we repeated
analyses excluding the first 6 months of follow-up on
ART. We examined whether CD4þ at ART start (<100
versus 100 cells/ml) modified effects of subtype on
mortality by testing for interaction.
We investigated mortality subsequent to viral failure,
because development of resistance has been found to vary
by subtype [29]. For those experiencing viral failure
(defined as two HIV RNA measurements >500 copies/
ml after achieving viral suppression) we estimated crude
and adjusted (for age, sex, CD4þ and AIDS at baseline,
period of starting ART, and regimen) MHR stratified by
cohort, region of origin, and risk. Follow-up was
measured from date of first detectable viral load. We
repeated analyses using unconfirmed viral failure, defined
as a single viral load greater than 500 copies/ml. Statistical
analyses were performed using Stata software (Version
12.0; College Station, Texas, USA).
Results
Eleven cohorts supplied data on 29 248 patients with
known HIV subtype who initiated ART in the study
period. We excluded patients with data missing on region
of origin (5536), CD4þ cell count (2482) and AIDS
diagnosis (62) at ART start, leaving 21 168 eligible
patients. A further 384 patients with rare subtypes (<100
cases, or equivalently <0.5% prevalence) were excluded
as they were too few to analyse. We analysed 20 784
patients who experienced 1172 deaths during 104 649
person-years of follow-up for an overall mortality rate of
11.2 [95% confidence interval (CI), 10.6–11.9] per 1000
person-years. The mortality rate in those excluded due to
missing data was higher at 19.5 (18.2–20.9) per 1000
person-years. Compared with included patients, a higher
proportion of those excluded started ART before 2003,
were IDU, came from SSA or America, and were infected
with subtypes A, C, or D.
Demographic and clinical characteristics of the study
population by subtype are shown in Table 1. Eighty-eight
per cent of patients were from European and 12% from
Canadian cohorts. Subtype B was most frequent [15 419/
20 784 (74%)], whereas subtype C was predominant
in those from SSA [1326/2091 (63%)]. Subtype
CRF02_AG was common in those from SSA, and
CRF01_AE was predominant in Asian patients. Subtype
B included the highest proportion of MSM 10 347 of
15 419 (67%) and IDU 1563 15 419 (10%), whereas
more than 50% of those with subtypes A, C, D, G and
CRF02_AG were female. Supplementary Figure 1,
http://links.lww.com/QAD/A818, shows the distri-
bution of subtypes for all patients and separately for
patients from SSA.
Older age, IDU and heterosexual (versus MSM) risk
group, lower CD4þ, AIDS diagnosis, starting ART pre
2003, and protease inhibitor-based (versus NNRTI-
based) regimen were associated with increased mortality
independently of viral subtype (supplementary Table 1,
http://links.lww.com/QAD/A818). Compared with
patients from EU, those from SSA, Australia and New
Zealand had lower, and indigenous Canadians higher risk
of mortality. Crude mortality was greatest for subtype B
(Table 2). However, after stratification by cohort (which
allows for between-cohort differences in mortality rates),
the highest MHR [1.13 (95% CI 0.85–1.50)] was for
subtype A. This was further increased to 1.78 (1.27–2.51)
in the model stratified by cohort, region of origin and risk
but was attenuated to 1.59 (1.13–2.23) after adjustment
for age, sex, CD4þ and AIDS at baseline, regimen, and
period of starting ART. There was little evidence that
mortality rates for other subtypes differed from those for
subtype B. AIC decreased substantially on stratification
showing improved fit to the data (Table 2). Crude and
adjusted MHR by subtype overall (N¼ 20 784) and
restricted to heterosexual and MSM Europeans
(N¼ 11 038) are compared in Fig. 1. Amongst European
MSM and heterosexuals, the adjusted MHR comparing
subtype A with B was greater 2.16 (1.43–3.26) than
among all patients 1.59 (1.13, 2.23) (supplementary
Table 2, http://links.lww.com/QAD/A818). In sensi-
tivity analyses restricted to different patient groups,
mortality for subtype A was consistently greater than for
subtype B (supplementary Table 2, http://links.lww.-
com/QAD/A818). The MHR for subtype A compared
with B was slightly reduced to 1.47 (95% CI, 1.01–2.13)
when patients who died within 6 months of starting
ART (N¼ 127) were excluded (supplementary Table 3,
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http://links.lww.com/QAD/A818). Patients with sub-
type A had worse prognosis than those with subtype B if
their CD4þ was less than 100 cells/ml [aMHR 2.65
(1.64–4.28)], but not if it was at least 100 cells/ml [0.95
(0.57–1.57)] at ART start (interaction P-value 0.0004,
supplementary Table 3, http://links.lww.com/QAD/
A818). In 40-year-old heterosexual males who started
NNRTI-based ARTafter 2003, the estimated absolute 2-
year mortality risk differences for subtype A compared
with B were 6 and 5% for those from EU and SSA,
respectively, in a high risk group (CD4þ 50 cells/ml and
AIDS at ART start), with no difference in a low risk
group (CD4þ 350 cells/ml and no AIDS diagnosis).
We further compared mortality in groups defined by both
subtype (restricted to A, B and C) and region of origin
(European MSM and heterosexuals compared with
patients from SSA). The cumulative mortality for these
six groups is shown in supplementary Figure 2, http://
links.lww.com/QAD/A818. For both Europeans and
those from SSA cumulative mortality was highest for
patients with subtype A infection. However, within each
subtype, the cumulative mortality was higher for patients
from EU compared with SSA for all three subtypes.
Table 3 shows the adjusted MHR for the six subtype-
origin combinations with EU subtype B as the
comparator. Adjusted MHR for all three subtypes were
higher in EU compared with SSA patients, although CIs
were wide (Table 3). In Europeans, those with subtype A
had the worst, and subtype C the best prognosis, whereas
within SSA, the order was A worst, and B best, although
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Fig. 1. Crude and adjusted mortality rate ratios by subtype
for all patients and restricted to European heterosexuals and
MSM. EU, European origin; het, heterosexual risk group.
Subtype B is the comparator; bars show 95% confidence
intervals. Crude model is stratified by cohort, region of origin,
and risk. Adjusted model is adjusted for age, sex, CD4þ cell
count and AIDS at baseline, period of starting ART, and
stratified by cohort, region of origin, and risk.
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all three adjusted MHR in SSA were quite similar with
overlapping CIs.
A total of 7865 patients experienced viral failure, of
whom 6834 were infected with subtypes A, B and C and
included in analyses. Of these, 736 died during 38 975
person-years of follow-up [mortality rate 18.9 (95% CI
17.6–20.3) per 1000 person-years]. Cumulative mortality
after viral failure was highest for subtype B (Supple-
mentary Figure 3, http://links.lww.com/QAD/A818).
The adjustedMHR after confirmed or unconfirmed viral
failure were similar for the three subtypes (Table 4).
Discussion
Patients treated with ART in Europe and Canada were
infected with diverse HIV-1 viral subtypes. Although
subtype B still constituted the majority of infections, over
a quarter were other subtypes, including a significant
number of infections with subtypes A and C, which are
common in Africans, and the two recombinant forms
CRF01AE and CRF02AG. We found a strong associ-
ation of transmission risk with viral subtype, with MSM
and IDU dominating subtype B, but heterosexual
transmission dominating other subtypes. Crude mortality
rates were highest for patients with subtype B, followed by
A and CRF01AE, whereas patients infected with
subtypes C, G and CRF02AG experienced lower
mortality rates. However we found that MHR were
highest for patients infected with subtype A after
stratification on cohort, region of origin and transmission
risk group, and adjustment for age, sex, CD4þ and AIDS
at baseline, period of starting ART, and regimen. There
was little difference in adjusted MHR between the other
subtypes. These results indicated that there was strong
confounding by region of origin in crude mortality rate
comparisons. Our finding of worse prognosis for patients
infected with subtype A compared with B was robust to
all sensitivity analyses which estimated adjusted MHR in
more homogeneous subgroups such as MSM and
heterosexually infected Europeans, or white heterosex-
uals, but only applied to patients who started ARTwith
CD4þ cell count less than 100 cells/ml. When we
compared mortality after viral failure, we found little
evidence of a difference in survival between subtypes A,
B, and C, but numbers of deaths after viral failure were
few for subtypes A and C.
This is the largest study of mortality according to viral
subtype to date: we analysed data on over 20 000 patients,
of whom more than 1000 died. Our results should be
generalizable to clinical settings in Europe and Canada
where there are migrants with HIV-1 infections of diverse
subtypes. Unlike many previous studies [23,24,30–32],
we analysed mortality among patients infected with nine
different subtypes or CRFs, rather than grouping non-B
subtypes together. Previous studies have found that viral
subtypes are compartmentalized by ethnicity and
transmission group which convey epidemiological infor-
mation [33–35], making it difficult to attribute
differences in prognosis to the influence of viral subtype.
We attempted to control for such confounding by
stratifying analyses on region of origin and risk group, as
well as by cohort. However, we had to use region of
origin as a proxy for ethnicity and some patients will have
been misclassified. We carried out sensitivity analyses
which restricted comparisons to more homogeneous
groups, such as MSM and heterosexuals of European
origin, and only white heterosexuals. We could only
compare the most frequently occurring subtypes (A, B
and C) in some subgroup analyses and also in analyses of
mortality subsequent to viral failure. We distinguished
black Caribbean and black Africans in the United
Kingdom, and white and black South Africans, and our
main results were not substantially changed in these
sensitivity analyses. There may have been misclassification
of risk group, particularly amongst black patients who
may be less likely to self-identify as MSM [36].
A limitation of our study was the exclusion of 8080 (28%)
patients with missing data on region of origin, CD4þ and
AIDS status at ART start. These patients had higher
mortality than those included in analyses. Whilst it is
likely that a higher proportion starting ART in earlier
years and IDU partially account for the increased
mortality, our results may be biased due to missing data.
In particular, patients from SSA and both North and
South America (compared with Europeans), and those
508 AIDS 2016, Vol 30 No 3
Table 3. Crude and adjusted (for age, sex, CD4R cell count and AIDS at baseline, period of starting ART, ART regimen) mortality hazard ratios
(MHR) comparing subtypes A, B, and C in EuropeanMSMand heterosexuals, and people from sub-Saharan Africa; models are stratified by cohort
and risk.
Deaths/N Crude MHR (95% CI) P value Adjusted MHR (95% CI) P value
EU subtype A 30/244 2.77 (1.85, 4.16) <0.001 2.26 (1.50, 3.42) <0.001
B 403/9637 1 1
C 13/413 0.75 (0.41, 1.36) 0.34 0.90 (0.49, 1.63) 0.72
SSA subtype A A 17/510 0.55 (0.31, 0.96) 0.13 0.75 (0.42, 1.33) 0.24
B 6/291 0.50 (0.20, 1.23) 0.04 0.58 (0.24, 1.43) 0.32
C 29/1326 0.51 (0.32, 0.82) 0.005 0.70 (0.43, 1.13) 0.14
TOTAL 498/12421
EU, European Union; CI, confidence interval; SSA, sub-Saharan Africa.
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
infected with subtypes A, C, and D (compared with B),
were more likely to have missing data. Therefore MHR
for subtypes A, C and D compared with B may be under-
estimated. Our finding of worse prognosis in those with
subtype Amay be affected by residual confounding due to
unmeasured social factors related to mortality rates. We
were unable to control for time from diagnosis to
treatment, and we lacked data on socio-economic status
and lifestyle factors such as smoking, alcohol and drug
abuse, which may be patterned by subtype and are related
to mortality. The majority of subtype A infections in the
United Kingdom were among Ugandans, categorized as
black African heterosexual transmission risk, who may
have had worse prognosis due to socio-economic
disadvantage and late presentation. There is also a high
prevalence of subtype A in Russia and Ukraine, where
IDU is a strong transmission factor, and to a lesser extent
in Greece and Cyprus. Only the EuroSIDA cohort
included patients treated in these countries. However, it is
likely that migrants from these countries were included in
cohorts from Austria, Germany, Switzerland and the
Netherlands as subtypes infecting immigrant patients
living in Europe are mostly similar to those causing
epidemics in their country of origin. We found that
amongst white Europeans with subtype A in these
cohorts, the prevalence of IDU was high. Such patients
may be disadvantaged due to the effects of historic or
ongoing substance abuse and/or socio-economic dis-
advantage. Among patients with subtypes A, B, and C, we
found that compared with Europeans, those from SSA
had lower mortality which may be due to a ‘‘healthy
migrant’’ effect, or to a healthier life-style: in particular
smoking prevalence may be lower in Africans than
Europeans [37]. Alternatively, there may have been
under-ascertainment of deaths in Africans or sicker
patients may have returned home.
The documented increasing diversity in viral subtypes
found in Canada and Europe [6,24,34] has been explained
by travel and HIV acquisition abroad [38], immigration
policy [39], and domestic transmission of non-B subtypes
[7]. In the UK CHIC study, which includes a large
immigrant population from SSA, diverse subtypes were
increasingly represented across all demographic groups,
which could be evidence of sexual mixing [34].
Several studies have considered the impact of viral subtype
on untreated HIV disease progression. Data from a
European seroconverter cohort showed that CD4þ at
seroconversion was higher for CRF01 and lower for C,
compared with B. Subsequent CD4þ decline was slower
for A, C, and CRF02_AG compared with B [40], but
viral load setpoint and time to AIDS or death did not
differ by subtype [40]. Subtype D may progress more
rapidly [9,19,41,42], whereas subtype A may have slower
disease progression [41,43]. Better prognosis of patients
from SSA compared with Europeans has been reported
for untreated patients. A Swiss study found that Africans
Mortality by viral subtypes 509
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had slower CD4þ decline than Europeans independently
of viral subtype [44], which might be related to host
factors allowing better tolerance of high levels of the virus
in Africans. Differential prognosis by subtype before
treatment with ART could have led to selection bias in
our study of prognosis from ART start.
Several previous studies have examined whether
response to ART differs by viral subtype [13,22,32]. A
UK study found that viral load suppression occurred
more rapidly in subtypes A and C compared with B, and
that virologic rebound occurred more rapidly in patients
with subtypeC, but other subtypeswere similar to B [13].
In the Greek cohort patients with subtype A had better
viral load response than those with B [22]. A large
collaboration of European cohorts found that risk of viral
failure was higher in those with subtype C and
CRF02_AG, and lower in A, compared with B [45].
In contrast, a Swiss study found that patients with non-B
subtypes had a lower risk of viral failure than B, but their
study was restricted to white patients and grouped all
non-B subtypes together [32]. Taken together, these
findings do not support the idea that worse prognosis in
subtype A is a consequence of either slower viral
suppression or higher risk of viral failure. The slow
natural progression of subtype A may lead to longer
duration of infection before treatment with accumulated
risks for non-AIDS complications of HIV. Additional
analyses of differences in causes of death between
subtypes would be useful.
Patients with subtype A may have poorer immunological
response to ART despite viral suppression. CD4þ
recovery rate after starting ART was similar in all
subtypes in a UK study,[13] and between A and B in a
Greek study [35]. A French study found better CD4þ
response in those with CRF02_AG compared with B.
However, a Belgian study did find that patients with
subtype A had the lowest CD4þ increase after starting
ART [46].
In conclusion, patients infected with subtype A may be at
a survival disadvantage compared with other subtypes
when they present with low CD4þ, although this may be
due to other epidemiological factors rather than subtype
per se. Although antiretroviral drugs have been designed
primarily for subtype B infections, there is little evidence
of disadvantage in those with non-B infection. Whilst
ART can achieve excellent outcomes in all patients
regardless of the infecting subtype, there remain many
factors that potentially limit recovery such as late
presentation to care, poor adherence to therapy, and
lack of social care. Such factors are likely to be more
important than viral subtype and, unlike subtype, are
modifiable risk factors. However, it is also possible that
real and important differences in prognosis between
subtypes that are driven by drug resistance are obscured by
such confounding factors
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